David Enscore, Ph.D. - Principal Scientist
David J. Enscore
advises 4P Therapeutics technology selection, product design goals, and analyzes results from product development studies.
Over the last several years, he
has provided product development direction to the pharmaceutical and medical device industries on a consulting basis.
focus is on controlled drug delivery products in general with a strong emphasis on transdermal drug delivery systems.
In a consulting role, he served as Interim Vice President of R&D at Micell Technologies, a company developing a sirolimus eluting, bioabsorbable polymer coated coronary artery stent.
He has served as an expert witness in several patent litigation cases involving transdermal technology.
Prior to starting his consulting business, Dr. Enscore was Senior Vice President, Product Research and Development at Altea Therapeutics and was responsible for all product development activities including pharmaceutical science, engineering, clinical R&D, quality assurance, and regulatory affairs.
Before joining Altea Therapeutics, he held senior R&D positions at Spherics, Incorporated, an advanced oral drug delivery company and Focal, Incorporated, a company that developed resorbable tissue sealants.
Prior to this, Dr. Enscore worked extensively in transdermal drug delivery, in various scientific and management positions, at Alza Corporation.
At Alza, he
lead the development of Nicoderm® CQ (transdermal nicotine), the second generation testosterone transdermal system (Testoderm® TTS), and the Actisite® tetracycline periodontal fiber.
has been granted 25 U.S. patents in controlled drug delivery and biodegrabable polymers.
Dr. Enscore received a BS and a PhD in Chemical Engineering, with a minor in Polymer Science, from North Carolina State University.